Info

Hovione is an international group dedicated to the cGMP development and manufacture of APIs, serving exclusively the pharmaceutical industry. With FDA inspected plants in Europe, the Far East and the US, Hovione is committed to the highest levels of service and quality. With a 50-year track record, Hovione offers advanced technologies as well as APIs for all drug delivery systems, from oral to injectable and from inhalation to topical applications. Specializing in complex chemistry and particle engineering, Hovione offers all services related to the development, manufacture and pre-formulation of both new chemical entities (NCEs) and existing APIs for off-patent products. Our aim is to do well what is difficult, to give our customers what they can not find elsewhere. Aiming to provide superior customer service, we take full responsibility for all matters relating to the API from pre-IND to NDA and beyond, ensuring fast and successful product launches. Hovione's reputation as a reliable long-term supplier has been built by delivering robust solutions to our customers on time, every time. The continuity and consistency of the service we provide is based on two essential factors: focus and thoroughness. Our specialist expertise in process chemistry enables us to address the complex issues associated with the development and manufacture of APIs and regulated intermediates. Our rigorous and systematic approach to project management is complemented by experienced staff with excellent technical and practical problem-solving skills. Together, these elements guarantee an unfailing and consistent quality of end-product and service. Hovione focuses its activities on the development and production of small molecules for demanding customers in the most highly regulated markets. We have produced over 45 different APIs at a commercial scale, developed more than 100 chemical processes at industrial scale and have filings in every country that has a specific API filing requirement. With worldwide yearly revenues of about US$100m, our main markets are North America (55% of sales), Europe (25%) and Japan (12%). Hovione employs 600 people worldwide and its 3 sites have a total reactor capacity of 530m3, ranging from lab to industrial ton scale. Hovione business is 50% custom synthesis for large Pharma and Biotech companies, 50% generic products. Our latest technologies in Particle Design and our new state-of-the-art cGMP Spray Drying installation enable us to provide our customers with solutions for Advanced APIs (aAPIsÔ), a step closer in the formulation pharma process.